Libre Duo Was FDA Authorized This Summer—So Where Is It?
If, like me, you were excited when Abbott’s Freestyle Libre Duo 10 Day received FDA authorization in August, you may be wondering: When can I actually get one?
Libre Duo combines continuous glucose and ketone monitoring in a single wearable sensor for people with diabetes. But FDA authorization and pharmacy availability are separate milestones. The wait raises practical questions about its release date and insurance coverage.
While we wait, let’s explore how Libre Duo works, why continuous ketone monitoring matters, who may benefit, and what we know about getting this new technology into your hands.
What is Libre Duo?
On August 25, 2026, the FDA authorized Abbott’s FreeStyle Libre Duo for people with diabetes ages 2 and older. This prescription sensor offers up to 10 days of wear and is the first wearable device to continuously monitor both glucose and ketones in a single sensor.
Current continuous glucose monitors measure glucose alone. Checking ketones typically requires a separate fingerstick blood test or urine test, providing a snapshot at one moment in time. Libre Duo adds continuous ketone monitoring, helping users see rising ketone levels that glucose readings alone might miss.
Why Is Early Ketone Detection So Important?
Millions of Americans rely on insulin to manage diabetes. When the body does not have enough insulin to use glucose effectively for energy, it begins breaking down fat, producing ketones. If ketones build up to dangerous levels, they can make the blood too acidic and lead to diabetic ketoacidosis (DKA), a potentially life-threatening emergency.
Recognizing rising ketones early gives people an opportunity to follow their ketone management plan and contact their diabetes team before the situation becomes more serious. That early warning may help prevent a traumatic hospital stay.
How Could Continuous Ketone Monitoring Close that Gap?
Without enough insulin, it’s shocking how quickly ketone levels can rise. In just a few hours, the situation can progress to diabetic ketoacidosis (DKA), a life-threatening emergency.
That’s why a device like Libre Duo could be a game changer for people with diabetes and their caregivers. Instead of relying on occasional ketone checks, Libre Duo continuously measures both glucose and ketones in the fluid just beneath the skin, every minute, day and night.
Readings are sent wirelessly to a compatible smartphone, where users can see their glucose and ketone levels and whether they’re trending up or down. Automatic alerts can flag concerning ketone levels, potentially giving people and their caregivers time to recognize a problem becomes an emergency.
When Will Libre Duo Be Available?
In short, we don’t know.
While the Libre Duo website does not list an official launch date, an October report from MassDevice suggested that Abbott plans to launch the sensor in December 2026.
FDA authorization allows Abbott to market Libre Duo, but it doesn’t mean you can fill a prescription just yet. We’re still waiting for confirmation of when ordering will open, which pharmacies or suppliers will carry the sensors, and what insurance coverage will look like.
Will Insurance Cover Libre Duo?
There are encouraging signs that insurance will cover Libre Duo, but we’re still waiting on the details. Reporting from Abbott’s third-quarter earnings call suggests Libre Duo coverage for people with type 1 diabetes could expand in early 2027.
CEO Robert Ford also discussed favorable U.S. insurance formulary changes taking effect January 1. Still, those comments don’t guarantee that your specific plan will cover Libre Duo or tell us what your copay will be.
For people with type 2 diabetes, coverage remains less clear. Medicare currently covers continuous glucose monitoring for eligible people who use insulin or have a documented history of problematic hypoglycemia, provided other requirements are met. That means some people who don’t use insulin can qualify, but these general rules do not confirm coverage for Libre Duo specifically.
What if I want to pay out of pocket?
Libre Duo’s cash price is still unclear.
For context, Abbott offers assistance that may bring the cost of two FreeStyle Libre 3 Plus sensors, a 30-day supply, to $75 for eligible commercially insured or uninsured users. That program does not establish what Libre Duo will cost or whether similar savings will be available.
Once ordering opens, a pharmacy or supplier can check specific benefits. Coverage, prior authorization requirements, and out-of-pocket costs will matter just as much as the launch date.
What Can You Do While You Wait for Libre Duo?
While we wait for more details about getting Libre Duo, one thing is clear: ketone monitoring already matters for people at higher risk of DKA. Here are my recommendations:
Check your supplies. Keep a working blood ketone meter with unexpired test strips or unexpired urine ketone strips on hand.
Review your sick-day plan. Do you know when to check for ketones and what to do if they’re elevated? If you’re unsure, ask your diabetes team to walk you through it.
Discuss whether Libre Duo is a good fit. Ask your care team how continuous ketone monitoring might help with your individual risks and treatment needs.
Watch for launch updates. Follow Abbott’s official announcements for ordering information and device compatibility.
Check your coverage. Once pharmacies or suppliers can process prescriptions, request a benefits check to understand coverage requirements and your out-of-pocket cost.
I’m excited about what Libre Duo could offer. But access to the sensor is only part of the picture. While we wait, having ketone-testing supplies on hand and knowing when and how to use them remains essential.
Frequently Asked Questions About Libre Duo
Libre Duo is a prescription sensor that continuously monitors both glucose and ketones. Standard CGMs measure glucose alone. Each Duo sensor offers up to 10 days of wear.
A U.S. launch is reportedly planned for December 2026. As of November 16, Abbott’s website still says “coming soon,” with exact ordering dates unconfirmed.
Libre Duo is FDA authorized for people with diabetes ages 2 and older. A diabetes care team can help determine who may benefit from continuous ketone monitoring.
Plan-specific coverage and cash pricing remain unclear. Coverage may expand in early 2027, but individual benefits and out-of-pocket costs will need verification.
Libre Duo may help detect rising ketones earlier, but it cannot guarantee DKA prevention. Readings should guide action alongside symptoms and an individualized ketone management plan.
Ready to Strengthen Diabetes Care and Education in Your Practice?
Are you looking to build, refine, or expand diabetes care and education services within your practice? I provide flexible, consultative support designed to meet the needs of busy clinics and healthcare organizations.
Diabetes care and education is central to my work. My approach focuses on translating current evidence and standards of care into clear, practical strategies that support sustainable behavior change and informed decision-making.
Let me help you develop patient-centered diabetes care and education that integrates seamlessly into clinical care. Book a discovery call to explore how we might work together.
Share this:
- Share on LinkedIn (Opens in new window) LinkedIn
- Share on X (Opens in new window) X
- Share on Facebook (Opens in new window) Facebook
- Share on WhatsApp (Opens in new window) WhatsApp
- Share on Reddit (Opens in new window) Reddit
- Email a link to a friend (Opens in new window) Email
- Print (Opens in new window) Print
Discover more from Sarah Hormachea
Subscribe to get the latest posts sent to your email.
You May Also Like
What Happens to Your Insulin Pump and CGM When You’re Hospitalized?
August 10, 2026
[Updated] Longevity Medicine Beyond the Messenger
February 3, 2026